Dextromethorphan and memantine after ketamine analgesia: a randomized control trial
| Affiliation auteurs | !!!! Error affiliation !!!! |
| Titre | Dextromethorphan and memantine after ketamine analgesia: a randomized control trial |
| Type de publication | Journal Article |
| Year of Publication | 2019 |
| Auteurs | Martin E, Sorel M, Morel V, Marcaillou F, Picard P, Delage N, Tiberghien F, Crosmary M-C, Najjar M, Colamarino R, Creach C, Lietar B, de Montgazon GBrumauld, Margot-Duclot A, Loriot M-A, Narjoz C, Lambert C, Pereira B, Pickering G |
| Journal | DRUG DESIGN DEVELOPMENT AND THERAPY |
| Volume | 13 |
| Pagination | 2677-2688 |
| Type of Article | Article |
| ISSN | 1177-8881 |
| Mots-clés | cognitive-affective status, drug relay, health-related quality of life, N-methyl-D-aspartate antagonists, peripheral neuropathic pain |
| Résumé | {Purpose: Intravenous ketamine is often prescribed in severe neuropathic pain. Oral N-methyl-D-aspartate receptor (NMDAR) antagonists might prolong pain relief, reducing the frequency of ketamine infusions and hospital admissions. This clinical trial aimed at assessing whether oral dextromethorphan or memantine might prolong pain relief after intravenous ketamine. Patients and methods: A multicenter randomized controlled clinical trial included 60 patients after ketamine infusion for refractory neuropathic pain. Dextromethorphan (90 mg/ day), memantine (20 mg/day) or placebo was given for 12 weeks (n=20 each) after ketamine infusion. The primary endpoint was pain intensity at one month. Secondary endpoints included pain, sleep, anxiety, depression, cognitive function and quality of life evaluations up to 12 weeks. Results: At 1 month, dextromethorphan maintained ketamine pain relief (Numeric Pain Scale: 4.01 +/- 1.87 to 4.05 +/- 2.61 |
| DOI | 10.2147/DDDT.S207350 |